TY - JOUR AU - de Boniface, Jana AU - Frisell, Jan AU - Andersson, Yvette AU - Bergkvist, Leif AU - Ahlgren, Johan AU - Rydén, Lisa AU - Olofsson Bagge, Roger AU - Sund, Malin AU - Johansson, Hemming AU - Lundstedt, Dan AU - Christiansen, Peer AU - Filtenborg Tvedskov, Tove AU - Offersen, Birgitte AU - Reimer, Toralf AU - Kühn, Thorsten AU - Kontos, Michalis AU - Gentilini, Oreste AU - on behalf of the SENOMAC Trialists’ Group PY - 2017 DA - 2017/05/26 TI - Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial JO - BMC Cancer SP - 379 VL - 17 IS - 1 AB - The role of axillary lymph node dissection (ALND) has increasingly been called into question among patients with positive sentinel lymph nodes. Two recent trials have failed to show a survival difference in sentinel node-positive breast cancer patients who were randomized either to undergo completion ALND or not. Neither of the trials, however, included breast cancer patients undergoing mastectomy or those with tumors larger than 5 cm, and power was debatable to show a small survival difference. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-017-3361-y DO - 10.1186/s12885-017-3361-y ID - de Boniface2017 ER -